PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...
NEW ORLEANS, LA—Use of enlicitide 20 mg, an oral PCSK9 inhibitor, significantly cut levels of LDL cholesterol and other atherogenic lipids in a large cohort of high-risk patients, results from the ...
Merck & Co. revealed the structure of an orally active and potent proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor macrocyclic peptide, MK-0616, which is being developed for the ...
Merck, known as MSD outside of the United States and Canada, announced positive topline results from the phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate, an ...
For those who play the high-stakes game of drug discovery, cholesterol-lowering PCSK9 inhibitors don’t seem anything like a sure bet. Patients will need to inject the drugs. They’re likely to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback